PortfoliosLab logo
ChromaDex Corporation (CDXC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US1710774076

CUSIP

171077407

IPO Date

Jul 15, 2008

Highlights

Market Cap

$611.90M

EPS (TTM)

$0.11

PE Ratio

71.55

Total Revenue (TTM)

$75.86M

Gross Profit (TTM)

$48.13M

EBITDA (TTM)

$9.19M

Year Range

$2.31 - $9.18

Target Price

$8.82

Short %

4.18%

Short Ratio

5.91

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ChromaDex Corporation

Popular comparisons:
CDXC vs. SPY CDXC vs. QBTS
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


CDXC

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of CDXC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20256.13%0.18%37.23%45.90%
20242.10%14.38%108.38%1.72%-22.03%-1.09%9.52%15.38%5.80%-4.38%121.20%-31.28%270.98%
202316.67%-14.80%-8.38%-13.73%6.82%11.35%9.55%-7.56%-8.18%-9.59%5.30%2.88%-14.88%
2022-24.87%-2.85%-9.89%-23.17%0.53%-12.11%2.99%-16.28%-14.58%23.58%13.16%-2.33%-55.08%
2021-1.25%193.88%-32.95%-4.93%-6.53%18.80%-11.87%-1.84%-26.49%-1.28%-24.23%-20.26%-22.08%
20202.32%-16.33%-11.65%53.37%-3.80%-4.57%10.24%-2.17%-18.99%12.47%9.98%-3.23%11.37%
2019-2.92%4.80%20.06%6.21%-10.56%16.83%-0.43%-15.55%0.64%-26.56%25.95%18.41%25.66%
2018-21.60%18.22%-22.94%-16.43%-3.99%10.09%20.75%1.12%-5.30%-18.88%2.01%-3.38%-41.67%
2017-16.01%-0.72%-2.54%15.61%5.47%16.46%-9.69%-2.61%27.98%-4.88%69.19%-15.03%77.64%
20169.02%0.75%5.97%4.46%17.30%-20.69%-3.38%-17.75%-9.42%-7.38%-11.96%36.21%-9.56%
20158.97%43.75%-5.07%-9.16%-0.17%1.85%-9.50%16.44%-12.94%28.83%-5.59%-9.63%38.48%
201410.53%2.38%6.40%-21.31%5.56%-14.47%3.08%-12.76%-7.61%-7.41%13.90%-22.65%-42.04%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 96, CDXC is among the top 4% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CDXC is 9696
Overall Rank
The Sharpe Ratio Rank of CDXC is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of CDXC is 9797
Sortino Ratio Rank
The Omega Ratio Rank of CDXC is 9595
Omega Ratio Rank
The Calmar Ratio Rank of CDXC is 9696
Calmar Ratio Rank
The Martin Ratio Rank of CDXC is 9595
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ChromaDex Corporation (CDXC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for ChromaDex Corporation. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


ChromaDex Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the ChromaDex Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ChromaDex Corporation was 97.00%, occurring on Aug 3, 2009. Recovery took 2854 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97%Sep 23, 200896Aug 3, 20092854Feb 25, 20212950
-93.65%Feb 26, 2021399Sep 26, 2022
-25%Jul 16, 20081Jul 16, 20081Jul 17, 20082
-22.22%Jul 29, 20083Aug 18, 20081Aug 19, 20084
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ChromaDex Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of ChromaDex Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 72.2% positive surprise.


-0.10-0.050.0020212022202320242025
0.03
-0.02
Actual
Estimate

Valuation

The Valuation section provides an overview of how ChromaDex Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for CDXC, comparing it with other companies in the Biotechnology industry. Currently, CDXC has a P/E ratio of 71.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for CDXC compared to other companies in the Biotechnology industry. CDXC currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CDXC relative to other companies in the Biotechnology industry. Currently, CDXC has a P/S ratio of 6.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for CDXC in comparison with other companies in the Biotechnology industry. Currently, CDXC has a P/B value of 11.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items